Avelumab first-line (1 L) maintenance for advanced urothelial carcinoma (aUC): Results from patients with ≥12 months of treatment in JAVELIN Bladder 100

被引：0

作者：

Aragon-Ching, Jeanny B. ^{[1
]}

Grivas, Petros ^{[2
]}

Loriot, Yohann ^{[3
]}

Bellmunt, Joaquim ^{[4
]}

Pook, David W. ^{[5
]}

Wang, Jing ^{[6
]}

Michelon, Elisabete ^{[7
]}

di Pietro, Alessandra ^{[8
]}

Powles, Thomas ^{[9
]}

Sridhar, Srikala S. ^{[10
]}

机构：

[1] Inova Schar Canc Inst, Fairfax, VA USA

[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA

[3] Univ Paris Saclay, INSERMU981, Gustave Roussy, Villejuif, France

[4] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA USA

[5] Monash Hlth, Dept Oncol, Melbourne, Vic, Australia

[6] Pfizer, Cambridge, MA USA

[7] Pfizer, New York, NY USA

[8] Pfizer Srl, Milan, Italy

[9] Queen Mary Univ London, St Bartholomews Hosp, Expt Canc Med Ctr, Barts Canc Inst, London, England

[10] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

228

引用

页码：138 / 139

页数：2